650 related articles for article (PubMed ID: 24334116)
1. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
2. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
4. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
5. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
[TBL] [Abstract][Full Text] [Related]
6. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
8. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
9. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
10. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
12. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
13. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
14. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
15. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
16. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
17. Lysosome-associated protein 1 (LAMP-1) and lysosome-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease.
Pereira EM; do Monte SJ; do Nascimento FF; de Castro JA; Sousa JL; Filho HC; da Silva RN; Labilloy A; Monte Neto JT; da Silva AS
Gene; 2014 Feb; 536(1):118-22. PubMed ID: 24334114
[TBL] [Abstract][Full Text] [Related]
18. Treatment of neutral glycosphingolipid lysosomal storage diseases via inhibition of the ABC drug transporter, MDR1. Cyclosporin A can lower serum and liver globotriaosyl ceramide levels in the Fabry mouse model.
Mattocks M; Bagovich M; De Rosa M; Bond S; Binnington B; Rasaiah VI; Medin J; Lingwood C
FEBS J; 2006 May; 273(9):2064-75. PubMed ID: 16724420
[TBL] [Abstract][Full Text] [Related]
19. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
20. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]